Evidence map›Paper›PMID 26342597›Full record

ArticleJournal of physiology and biochemistry2015

Protective effects of Phyllanthus emblica against myocardial ischemia-reperfusion injury: the role of PI3-kinase/glycogen synthase kinase 3β/β-catenin pathway.

Mahesh Thirunavukkarasu, Vaithinathan Selvaraju, Leonidas Tapias, Juan A Sanchez, J Alexander Palesty, Nilanjana Maulik

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of physiology and biochemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Functional and Nutraceutical Significance of Amla (Antioxidants (Basel, Switzerland) · 2022
    Review
  6. Review
  7. Article
  8. Cardioprotective Properties ofFrontiers in molecular biosciences · 2021
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. A systematic review on the cardiovascular pharmacology ofJournal of cardiovascular and thoracic research · 2018
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Mahesh ThirunavukkarasuMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, USA. mthirunavukkarasu@uchc.edu.
Vaithinathan SelvarajuMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, USA.
Leonidas TapiasMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, USA.
Juan A SanchezMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, USA.
J Alexander PalestyDepartment of Surgery, Saint Mary's Hospital, Waterbury, CT, USA.
Nilanjana MaulikMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, USA. nmaulik@uchc.edu.
UConn Health · USSt Mary's Hospital · USUniversity of Saint Mary · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical studies of Phyllanthus emblica (P. emblica) have shown that it increases production of nitric oxide, glutathione, and high-density lipoprotein (HDL); decreases low-density lipoprotein (LDL), total cholesterol, triglycerides, and high-sensitivity C-reactive protein (hsCRP); and significantly inhibits platelet aggregation. The following study was designed to examine the effect of P. emblica treatment on myocardial ischemia-reperfusion (I/R) injury and identify the molecular targets and its underlying mechanism(s). Experimental animals were divided into four groups: control sham (CS), P. emblica sham (PS), control I/R (CIR), and P. emblica I/R (PIR). Rats in the P. emblica groups were gavaged with aqueous P. emblica solution (100 mg/kg body weight) for 30 days. After 30 days of gavaging, the I/R group underwent I/R surgery (45-min ischemia) followed by 4 or 30 days of reperfusion. Rats in the sham group underwent surgery without ligation. Left ventricular tissue samples, 4 and 30 days after I/R, were used for Western blot analysis and immunohistochemistry, respectively. Western blot analysis showed upregulation of phosphorylated Akt and GSK3-β and increased nuclear translocation of β-catenin in the PIR group versus CIR. PIR rats also indicated reduced 3-nitrotyrosine and Caspase-3 expression. Increased phosphorylation of endothelial nitric oxide synthase (p-eNOS) and upregulation of anti-apoptotic protein Bcl-2 were found in the PIR group. Echocardiography showed increased ejection fraction and fractional shortening and decreased left ventricular internal diameter in experimental subjects compared to controls. There was decreased fibrosis in P. emblica-treated rats compared to controls. The results of this study indicate that P. emblica is capable of upregulating the PI3K/Akt/GSK3β/β-catenin cardioprotective pathway, thereby preserving cardiac tissue during ischemia-reperfusion injury.

Indexed as

Wnt Signaling PathwayAnimalsApoptosisbeta CateninCardiotonic AgentsDrug Evaluation, PreclinicalGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaMaleMyocardial Reperfusion InjuryMyocardiumPhosphatidylinositol 3-KinasesPhosphorylationPhyllanthus emblicaPlant ExtractsProtein Processing, Post-Translationalbeta CateninCardiotonic AgentsCtnnb1 protein, ratGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaGsk3b protein, ratPhosphatidylinositol 3-KinasesPlant ExtractsProto-Oncogene Proteins c-aktApoptosisFibrosisGlycogen synthase kinase 3βIschemia reperfusionPhyllanthus emblica

Identifiers

PMID26342597
OpenAlexW1435175130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.